Clinical Scorecard: FDA Broadens CFTR Therapy Eligibility
At a Glance
| Category | Detail |
|---|---|
| Condition | Cystic Fibrosis |
| Key Mechanisms | CFTR modulator therapy targeting defective CFTR protein function. |
| Target Population | Patients aged 6 years and older for vanzacaftor/tezacaftor/ivacaftor; 2 years and older for elexacaftor/tezacaftor/ivacaftor and ivacaftor. |
| Care Setting | Outpatient clinical settings. |
Key Highlights
- Expanded eligibility to approximately 95% of CF patients in the US.
- Increased access for about 800 additional patients.
- Supported by clinical and in vitro data for 564 and 521 variants respectively.
- Therapies address the underlying cause of CF.
- Common adverse reactions include cough, headache, and elevated liver enzymes.
Guideline-Based Recommendations
Diagnosis
- Evaluate CFTR gene variants for responsiveness.
Management
- Initiate therapy based on CFTR variant analysis.
Monitoring & Follow-up
- Liver function tests prior to initiation, monthly for 6 months, every 3 months for 12 months, and annually thereafter.
Risks
- Monitor for elevated transaminases and potential drug-induced liver injury.
Patient & Prescribing Data
Cystic fibrosis patients with specific CFTR gene variants.
Use is not recommended in moderate to severe hepatic impairment unless benefits outweigh risks.
Clinical Best Practices
- Conduct thorough variant analysis to determine eligibility.
- Implement regular liver function monitoring.
- Educate patients on potential adverse reactions and drug interactions.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
